期刊文献+

血清标志物联合检测在原发性肝癌中的临床应用 被引量:1

原文传递
导出
摘要 目的探讨血清高尔基体蛋白73(GP73)、甲胎蛋白异质体3(AFP-L3)、磷脂酰基醇蛋白聚糖3(GPC-3)联合检测在原发性肝癌(PHC)中的临床应用价值。方法选取北华大学附属医院PHC患者52例(PHC组),肝炎后肝硬化(LC)60例(LC组),同期健康体检者70例(对照组)。比较3组研究对象GPC-3、GP73、AFP-L3的血清水平及各项指标联合检测的临床意义。结果 PHC组GPC-3、GP73、AFP-L3的血清水平明显高于其他两组,差异有统计学意义(P<0.05)。单项检测GP73灵敏度为78.3%和准确率为85.3%最高。AFP-L3特异性最高为92.6%。血清GP73、GPC-3、AFP-L3三项联合检测的特异性、灵敏度、准确率均明显高于单项检测,差异有统计学意义(P<0.05)。结论血清GP73、GPC-3、AFP-L3联合检测能有效提高PHC的检出率,有助于尽早确诊PHC并及时制订有效的治疗方案。
出处 《中国城乡企业卫生》 2019年第3期200-201,共2页 Chinese Journal of Urban and Rural Enterprise Hygiene
基金 吉林省自然科学基金(20160101160JC)
  • 相关文献

参考文献7

二级参考文献149

  • 1Giuseppe Cabibbo,Marcello Maida,Chiara Genco,Pietro Parisi,Marco Peralta,Michela Antonucci,Giuseppe Brancatelli,Calogero Cammà,Antonio Craxì,Vito Di Marco.untreatable hepatocellular 癌的自然历史: 回顾的队研究[J].World Journal of Hepatology,2012,4(9):256-261. 被引量:11
  • 2Alexander J. Thompson,Andrew J. Muir,Mark S. Sulkowski,Dongliang Ge,Jacques Fellay,Kevin V. Shianna,Thomas Urban,Nezam H. Afdhal,Ira M. Jacobson,Rafael Esteban,Fred Poordad,Eric J. Lawitz,Jonathan McCone,Mitchell L. Shiffman,Greg W. Galler,William M. Lee,Robert Reindollar,John W. King,Paul Y. Kwo,Reem H. Ghalib,Bradley Freilich,Lisa M. Nyberg,Stefan Zeuzem,Thierry Poynard,David M. Vock,Karen S. Pieper,Keyur Patel,Hans L. Tillmann,Stephanie Noviello,Kenneth Koury,Lisa D. Pedicone,Clifford A. Brass,Janice K. Albrecht,David B. Goldstein,John G. McHutchison.Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus[J]. Gastroenterology . 2010 (1)
  • 3Llovet Josep M,Ricci Sergio,Mazzaferro Vincenzo,Hilgard Philip,Gane Edward,Blanc Jean-Frédéric,de Oliveira Andre Cosme,Santoro Armando,Raoul Jean-Luc,Forner Alejandro,Schwartz Myron,Porta Camillo,Zeuzem Stefan,Bolondi Luigi,Greten Tim F,G.Sorafenib in advanced hepatocellular carcinoma. The New England Quarterly . 2008
  • 4B Taouli,DM Koh.Diffusion-weighted MR imaging of the liver. Radiology . 2010
  • 5Pugh R N,Murray-Lyon I M,Dawson J L,Pietroni M C,Williams R.Transection of the oesophagus for bleeding oesophageal varices. The British journal of surgery . 1973
  • 6Ann-Lii Cheng,Yoon-Koo Kang,Zhendong Chen,Chao-Jung Tsao,Shukui Qin,Jun Suk Kim,Rongcheng Luo,Jifeng Feng,Shenglong Ye,Tsai-Sheng Yang,Jianming Xu,Yan Sun,Houjie Liang,Jiwei Liu,Jiejun Wang,Won Young Tak,Hongming Pan,Karin Burock,Jessie Zou,Dimitris Voliotis,Zhongzhen Guan.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial[J].Lancet Oncology.2009(1)
  • 7Riccardo Lencioni,Josep Llovet.Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma[J].Semin Liver Dis.2010(01)
  • 8Shukui Qin,Yuxian Bai,Ho Yeong Lim,Sumitra Thongprasert,Yee Chao,Jia Fan,Tsai-Shen Yang,Vajarabhongsa Bhudhisawasdi,Won Ki Kang,Yu Zhou,Jee Hyun Lee,Yan Sun.Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia[J].Journal of Clinical Oncology.2013(28)
  • 9Vincenzi Bruno,Santini Daniele,Russo Antonio,Addeo Raffaele,Giuliani Francesco,Montella Liliana,Rizzo Sergio,Venditti Olga,Frezza Anna Maria,Caraglia Michele,Colucci Giuseppe,Del Prete Salvatore,Tonini Giuseppe.Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. The Oncologist . 2010
  • 10Maria Reig,Ferran Torres,Carlos Rodriguez-Lope,Alejandro Forner,Neus LLarch,Jordi Rimola,Anna Darnell,José Ríos,Carmen Ayuso,Jordi Bruix.Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib[J]. Journal of Hepatology . 2014

共引文献68

同被引文献5

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部